Potassium Chloride 0.3% And Glucose 5% Soln For Infusion Bp
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Potassium Chloride 0.3% w/v and Glucose 5% w/v Solution for Infusion - BP.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Potassium Chloride: 3.0 g/l
Glucose (as monohydrate): 50.0 g/l
mmol/l: K+: 40 Cl-: 40
For the full list of excipients: see 6.1.
3 PHARMACEUTICAL FORM
Solution for infusion.
Clear solution, free from visible particles.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Prevention and treatment of potassium depletion and/or hypokalaemia in cases where supply of water and carbohydrates is required, due to restriction of the intake of fluids and electrolytes by normal routes.
4.2 Posology and method of administration
Posology
Adults, the Elderly and Children
Doses may be expressed in terms of mEq or mmol of potassium, mass of potassium, or mass of potassium salt:
1 g KCl = 525 mg of K+ or 13.4 mEq or 13.4 mmol of K+ and Cl 1 mmol K+ = 39.1 mg K+.
The dosage of this solution depends on the age, weight, clinical and biological (acid-base balance) conditions of the patient, concomitant therapy and in particular the patient’s hydration state.
General posology
The recommended dosage for the treatment of carbohydrates and fluid depletion is
- for adults: 500 ml to 3 litres/24h
- for babies and children:
- 0-10 kg body weight: 100 ml/kg/24h
- 10-20 kg body weight: 1000 ml + (50 ml /kg over 10 kg) /24h
- >20 kg body weight: 1500 ml + (20 ml/kg over 20 kg)/24h
The infusion rate should not exceed the patient’s glucose oxidation capacities in order to avoid hyperglycaemia. Therefore the maximum dose ranges from 5mg/kg/min for adults to 10-18 mg/kg/min for babies and children depending on the age and the total body mass.
Posology for prevention and treatment ofpotassium depletion
A typical dose of potassium for the prevention of hypokalaemia may be up to 50 mmoles daily and similar doses may be adequate in mild potassium deficiency. The maximal recommended dose of potassium is 2 to 3 mmol/kg/24h.
When used for the treatment of hypokalaemia, the recommended dosage is 20 mmoles of potassium over 2 to 3 hours (i.e. 7-10 mmol/h) under ECG control.
The maximum recommended administration rate should not exceed 15-20 mmol/h.
Patients with renal impairment should receive lower doses.
In any case, the dosage given under “General Posology” should not be exceeded.
Use in Paediatric Population:
The infusion rate and volume depends on the age, weight, clinical and metabolic conditions of the patient, concomitant therapy and should be determined by the consulting physician experienced in paediatric intravenous fluid therapy (see Section 4.4).
Method of administration
Route of administration
The administration is performed by intravenous route using sterile and non-pyrogenic equipment.
Intravenous potassium should be administered via a large peripheral or central vein to diminish the risk of causing sclerosis. If infused through central vein, be sure the catheter is not in the atrium or ventricle to avoid localised hyperkalaemia.
Solutions containing potassium should be administered slowly.
As administered intravenously, potassium should not be given faster than 15 to 20 mmoles/h to avoid dangerous hyperkalaemia.
Monitoring
Adequate urine flow must be ensured and careful monitoring of plasma-potassium and other electrolyte concentrations is essential. Higher dosage or high speed infusion must be performed under ECG control.
4.3 Contraindications
The solution is contraindicated in patients presenting:
- Hyperchloremia and hyperkalaemia that are not related to the concentration effect associated to a volume depletion
- Severe renal insufficiency (with oliguria/anuria)
- Uncompensated cardiac failure
- Addison’s disease.
The solution is also contraindicated in cases of uncompensated diabetes, other known glucose intolerances (such as metabolic stress situations), hyperosmolar coma, hyperglycaemia, hyperlactatemia.
4.4 Special warnings and precautions for use
Potassium Chloride 0.3% and Glucose 5% solution is a hypertonic solution, with an approximate osmolarity of 358 mOsm/l.
High volume infusion must be used under specific monitoring in patients with cardiac or pulmonary failure.
Administration should be carried out under regular and careful surveillance. Regular monitoring of clinical status, blood glucose level, plasma electrolyte concentrations, plasma creatinine levels, BUN level, acid-base balance and ECG is essential in patients receiving potassium therapy, particularly those with cardiac or renal impairment. Adequate urine flow must be ensured and fluid balance should be monitored.
Potassium salts should be administered with considerable care to patients with cardiac disease (myocardial infarction, cardiac arrhythmias) or conditions predisposing to hyperkalaemia such as renal or adrenocortical insufficiency, acute dehydration, or extensive tissue destruction as occurs with severe burns. Infusion of solutions containing glucose could be contraindicated in the first 24 hours following head trauma and blood glucose concentration should be closely monitored during intracranial hypertension episodes.
Administration of glucose containing solutions may lead to hyperglycaemia. In this case, it is recommended not to use this solution after acute ischemic strokes
as hyperglycaemia has been implicated in increasing cerebral ischemic brain damage and impairing recovery.
If hyperglycaemia occurs, rate of infusion should be adjusted or insulin administered.
In diabetic patients, the amount of infused glucose has to be taken into account and insulin requirements may be modified.
Due to the risk of pseudo-agglutination precipitated by its glucose content, Potassium Chloride 0.3% and Glucose 5% solution must not be added to or administered simultaneously through the same tubing with citrate anticoagulated/preserved blood.
During long term treatment, a convenient nutritive treatment supply must be given to the patient.
Hypersensitivity/infusion reactions, including anaphylactoid reactions may occur. The infusion must be stopped immediately if signs or symptoms of a suspected hypersensitivity reaction develop. Appropriate therapeutic countermeasures must be instituted as clinically indicated. Solutions containing glucose should be used with caution in patients with known allergy to corn or corn products (see section 4.8).
Paediatric Population
Newborns - especially those born premature and with low birth weight - are at increased risk of developing hypo- or hyperglycaemia and therefore need close monitoring during treatment with intravenous glucose solutions to ensure adequate glycaemic control in order to avoid potential long term adverse effects. Hypoglycaemia in the newborn can cause prolonged seizures, coma and brain damage. Hyperglycaemia has been associated with intraventricular haemorrhage, late onset bacterial and fungal infection, retinopathy of prematurity, necrotizing enterocolitis, bronchopulmonary dysplasia, prolonged length of hospital stay, and death.
In order to avoid potentially fatal over infusion of intravenous fluids to the neonate, special attention needs to be paid to the method of administration. When using a syringe pump to administer intravenous fluids or medicines to neonates, a bag of fluid should not be left connected to the syringe.
When using an infusion pump all clamps on the intravenous administration set must be closed before removing the administration set from the pump, or switching the pump off. This is required regardless of whether the administration set has an anti free flow device.
The intravenous infusion device and administration equipment must be frequently monitored.
Plasma electrolyte concentrations should be closely monitored in the paediatric population as this population may have impaired ability to regulate fluids and electrolytes. The infusion of hypotonic fluids together with the non-osmotic secretion of ADH may result in hyponatraemia. Hyponatraemia can lead to headache, nausea, seizures, lethargy, coma, cerebral oedema and death, therefore acute symptomatic hyponatraemic encephalopathy is considered a medical emergency.
4.5 Interaction with other medicinal products and other forms of interaction
Solutions containing potassium should be used with caution in patients receiving drugs that increase plasma-potassium concentrations (e.g. potassium-sparing diuretics, ACE inhibitors, Angiotension II receptors antagonists, ciclosporin, tacrolimus and drugs that contain potassium).
Glucose should not be administered through the same infusion equipment as whole blood as haemolysis and clumping can occur (see section 4.4).
4.6 Fertility, pregnancy and lactation
Hyperkalaemic and hypokalaemic serum levels lead to impaired cardiac function of the maternal and foetal hearts. Therefore, maternal electrolyte levels must be controlled regularly.
As long as the maternal electrolyte serum levels are kept within the physiological range, there are no potential concerns regarding administration of Potassium Chloride 0.3% and Glucose 5% solution during pregnancy and lactation.
4.7 Effects on ability to drive and use machines
None known.
4.8 Undesirable effects
Adverse reactions may be associated to the technique of administration including febrile response, infection at the site of injection, local pain or reaction, vein irritation, venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolemia.
In case of undesirable effect(s), the infusion must be discontinued.
Anaphylactic reaction, hypersensitivity, and chills have also been reported.1 1Reported for similar solutions containing dextrose.
Table 1
|
Ta |
mlated list of adverse reactions | |
|
System Organ Class |
Symptoms (LLT terms MedDRA) |
Frequency |
|
Immune system disorders |
Allergic reaction Anaphyl actic reaction** Hypersensitivity** |
Not known (*) |
|
Metabolism and nutrition disorders |
Hypervolaemia, | |
|
Skin and subcutaneous tissue disorders |
Sweating | |
|
General disorders and administration site conditions |
Chills**, Shivering Febrile reaction, Fever Infection at site of injection Thrombophlebitis | |
(*) cannot be estimated from the available data
(**) Potential manifestation in patients with allergy to corn, see section 4.4.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme.
Website: www.mhra.gov.uk/yellowcard
4.9 Overdose
Excessive administration of potassium may lead to the development of hyperkalaemia, especially in patients with renal impairment. Symptoms include paresthesia of the extremities, muscle weakness, paralysis, cardiac arrhythmias, heart block, cardiac arrest, and mental confusion.
One of the important indicators of potassium toxicity are ECG changes including tall, peaked T-waves, depression of S-T segment, disappearance of the P-wave, prolongation of the Q-T interval, and widening and slurring of the QRS complex.
Treatment of hyperkalaemia involves the administration of calcium, insulin or sodium bicarbonate, and exchange resins or dialysis.
Excessive administration of chloride salts may cause a loss of bicarbonate with an acidifying effect.
In the event of accidental over infusion, treatment should be discontinued and the patient should be observed for the appropriate signs and symptoms related to the drug
administered. The relevant symptomatic and supportive measures should be provided as necessary.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group (ATC code): “electrolytes with carbohydrates” (B05BB02).
Potassium chloride 0.3% and Glucose 5% is an hypertonic solution of electrolytes and glucose, with an approximate osmolarity of 358 mOsm/l.
The pharmacodynamic properties of this solution are those of its components (potassium, chloride and glucose).
Potassium is predominantly an intracellular cation, primarily found in muscle; only about 2% is present in the extracellular fluid. It is essential for numerous metabolic and physiological processes including nerve conduction, muscle contraction, and acid-base regulation.
Chloride is mainly an extracellular anion. Intracellular chloride is in high concentration in red blood cells and gastric mucosa.
Glucose is the principal source of energy in cellular metabolism.
5.2 Pharmacokinetic properties
The pharmacokinetic properties of Potassium Chloride 0.3% and Glucose 5% are those of its components (potassium, chloride and glucose).
Intravenous administration of this solution provides an immediate supply of electrolytes and glucose to blood.
Factors influencing potassium transfer between intracellular and extracellular fluid such as acid-base disturbances can distort the relationship between plasma concentrations and total body stores. Potassium is excreted mainly by the kidneys; it is secreted in the distal tubules in exchange for sodium or hydrogen ions. The capacity of the kidneys to conserve potassium is poor and some urinary excretion of potassium continues even when there is severe depletion. Some potassium is excreted in the faeces and small amounts may also be excreted in sweat.
The two main metabolic pathways of glucose are gluconeogenesis (energy storage) and glycogenolysis (energy release). Glucose metabolism is regulated by insulin.
5.3
Preclinical safety data
Preclinical safety data of Potassium Chloride 0.3% and Glucose 5% solution in animals are not relevant since potassium chloride and glucose are physiological components of the body.
Toxic effects are not to be expected if serum electrolytes are kept within physiological range.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
- Hydrochloric acid, concentrated
- Water for Injections.
6.2 Incompatibilities
As with all parenteral solutions incompatibility of the additive medications with the solution must be assessed before addition.
In the absence of compatibility studies, this solution must not be mixed with other medicinal products.
It is the responsibility of the physician to judge the incompatibility of an additive medication with this solution by checking for eventual colour change and/or eventual precipitate, insoluble complexes or crystals apparition. The Instructions for Use of the medication to be added must be consulted.
Before adding a drug, verify it is soluble and/or stable in water at the pH of Potassium Chloride 0.3% w/v and Glucose 5% w/v solution (pH: 3.5 to 6.5).
As a guidance, the following medications are incompatible with the Potassium Chloride 0.3 % and Glucose 5 % solution (non-exhaustive listing):
- Amphotericin B
- Dobutamine
Glucose should not be administered through the same infusion equipment as whole blood as haemolysis and clumping can occur (see section 4.4).
Those additives known to be incompatible should not be used.
6.3 Shelf life
Shelf life as packaged: 500 ml: 24 months 1000 ml: 36 months
In-use shelf life
Chemical and physical stability of any additive medication at the pH of the Potassium Chloride 0.3% and Glucose 5% Solution in the Viaflo container should be established prior to use. From a microbiological point of view, the diluted product must be used immediately unless dilution has taken place under controlled and validated aseptic conditions. If not used immediately, in-use storage times and conditions are the responsibility of the user.
6.4 Special precautions for storage
No special precautions for storage
6.5 Nature and contents of container
The bags known as Viaflo are composed of polyolefin/polyamide co-extruded plastic (PL 2442).
The bags are overwrapped with a protective plastic overpouch composed of polyamide/polypropylene.
The bag size is either 500 or 1000 ml.
Outer carton contents: - 20 bags of 500 ml or - 10 bags of 1000ml.
6.6 Special precautions for disposal and other handling
Use only if the solution is clear, without visible particles and if the container is undamaged. Administer immediately following the insertion of infusion set.
Do not remove unit from overwrap until ready for use.
The inner bag maintains the sterility of the product.
Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before the administration of the fluid from the secondary container is completed.
Pressurizing intravenous solutions contained in flexible plastic containers to increase flow rates can result in air embolism if the residual air in the container is not fully evacuated prior to administration.
Use of a vented intravenous administration set with the vent in the open position could result in air embolism. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers.
The solution should be administered with sterile equipment using an aseptic technique. The equipment should be primed with the solution in order to prevent air entering the system.
Additives may be introduced before or during infusion through the injection site. When additive is used, verify isotonicity prior to parenteral administration. Thorough and careful aseptic mixing of any additive is mandatory. Solutions containing additives should be used immediately and not stored.
Adding medication or using an incorrect administration technique may cause the appearance of fever reactions due to the possible introduction of pyrogens.
In the case of adverse reaction, infusion must be stopped immediately.
Discard after single use.
Discard any unused portion.
Do not reconnect partially used bags.
1. Opening
a. Remove the Viaflo container from the overpouch just before use.
b. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution, as sterility may be impaired.
c. Check the solution for limpidity and absence of foreign matters. If solution is not clear or contains foreign matters, discard the solution.
2. Preparation for administration
Use sterile material for preparation and administration
a. Suspend container from eyelet support.
b. Remove plastic protector from outlet port at bottom of container:
- grip the small wing on the neck of the port with one hand,
- grip the large wing on the cap with the other hand and twist,
- the cap will pop off.
c. Use an aseptic method to set up infusion.
d. Attach administration set. Refer to complete directions accompanying set for connection, priming of the set and administration of the solution.
3. Techniques for injection of additive medications
Warning: Additives may be incompatible.
To add medication before administration
a.
Disinfect medication site.
b. Using a syringe with 19 to 22 gauge needle, puncture resealable medication port and inject.
c. Mix solution and medication thoroughly. For high-density medication such as potassium chloride, tap the ports gently while ports are upright and mix.
Caution: Do not store bags containing added medications.
To add medication during administration
a. Close clamp on the set.
b. Disinfect medication site.
c. Using a syringe with 19 to 22 gauge needle, puncture resealable medication port and inject.
d. Remove container from IV pole and/or turn to an upright position.
e. Evacuate both ports by tapping gently while the container is in an upright position.
f. Mix solution and medication thoroughly.
g. Return container to in use position and continue administration.
7 MARKETING AUTHORISATION HOLDER
Baxter Healthcare Ltd.
Caxton Way Thetford Norfolk IP24 3SE United Kingdom
8 MARKETING AUTHORISATION NUMBER(S)
PL 00116/0339
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION 29/09/2006
10 DATE OF REVISION OF THE TEXT
19/06/2015